Christopher  Dinsmore net worth and biography

Christopher Dinsmore Biography and Net Worth

Insider of Kronos Bio
Chris joined Kronos Bio in 2020 as Chief Scientific Officer after 26 years of experience in biomedical R&D. He joined Kronos Bio from Third Rock Ventures, where he was an Entrepreneur-in-Residence focusing on discovering and launching new innovative therapeutic companies. Previously, he was Vice President and Head of Chemistry at FORMA Therapeutics, responsible for the advancement of a pipeline of transformative medicines and applying an array of discovery chemistry platforms and approaches to target classes in epigenetics and protein homeostasis. Earlier, Chris was at Merck Research Laboratories for 19 years where he held various positions in medicinal chemistry. His project experiences in discovery and development have been in therapeutic categories that include cancer, hematology, sickle cell disease, asthma, and rheumatoid arthritis, leading to the advancement of numerous development compounds into clinical trials. Chris also serves as a member of the WARF Therapeutics Advisory Board, helping to move therapeutic innovations forward in drug discovery and development. After graduating from Bowdoin College with a bachelor’s degree in chemistry and art, he earned his Ph.D. in synthetic organic chemistry from the University of Minnesota in Minneapolis, and then carried out postdoctoral research in chemical synthesis at Harvard University.

What is Christopher Dinsmore's net worth?

The estimated net worth of Christopher Dinsmore is at least $339,259.70 as of January 4th, 2024. Dr. Dinsmore owns 260,969 shares of Kronos Bio stock worth more than $339,260 as of March 29th. This net worth estimate does not reflect any other investments that Dr. Dinsmore may own. Learn More about Christopher Dinsmore's net worth.

How do I contact Christopher Dinsmore?

The corporate mailing address for Dr. Dinsmore and other Kronos Bio executives is , , . Kronos Bio can also be reached via phone at 650-781-5200 and via email at [email protected]. Learn More on Christopher Dinsmore's contact information.

Has Christopher Dinsmore been buying or selling shares of Kronos Bio?

During the last ninety days, Christopher Dinsmore has sold $8,691.88 in shares of Kronos Bio stock. Most recently, Christopher Dinsmore sold 7,366 shares of the business's stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $1.18, for a transaction totalling $8,691.88. Following the completion of the sale, the insider now directly owns 260,969 shares of the company's stock, valued at $307,943.42. Learn More on Christopher Dinsmore's trading history.

Who are Kronos Bio's active insiders?

Kronos Bio's insider roster includes Norbert Bischofberger (CEO), Marianne De Backer (Director), Jorge DiMartino (VP), Christopher Dinsmore (Insider), and Jakob Loven (Director). Learn More on Kronos Bio's active insiders.

Are insiders buying or selling shares of Kronos Bio?

During the last year, Kronos Bio insiders bought shares 2 times. They purchased a total of 1,468,623 shares worth more than $1,202,320.20. During the last year, insiders at the sold shares 9 times. They sold a total of 91,887 shares worth more than $126,186.03. The most recent insider tranaction occured on February, 21st when SVP Elizabeth A Olek sold 7,368 shares worth more than $7,736.40. Insiders at Kronos Bio own 23.4% of the company. Learn More about insider trades at Kronos Bio.

Information on this page was last updated on 2/21/2024.

Christopher Dinsmore Insider Trading History at Kronos Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2024Sell7,366$1.18$8,691.88260,969View SEC Filing Icon  
12/12/2023Sell10,032$1.30$13,041.60268,335View SEC Filing Icon  
7/6/2023Sell6,634$1.75$11,609.50278,367View SEC Filing Icon  
2/24/2023Sell6,291$1.74$10,946.34285,001View SEC Filing Icon  
12/12/2022Sell9,138$1.81$16,539.78162,936View SEC Filing Icon  
12/13/2021Sell11,386$12.37$140,844.82View SEC Filing Icon  
10/4/2021Sell9,189$20.81$191,223.09View SEC Filing Icon  
9/7/2021Sell9,189$21.91$201,330.99105,549View SEC Filing Icon  
8/2/2021Sell9,189$20.59$189,201.51105,549View SEC Filing Icon  
See Full Table

Christopher Dinsmore Buying and Selling Activity at Kronos Bio

This chart shows Christopher Dinsmore's buying and selling at Kronos Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kronos Bio Company Overview

Kronos Bio logo
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. The company's lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. Kronos Bio, Inc. was incorporated in 2017 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $1.30
Low: $1.22
High: $1.35

50 Day Range

MA: $1.13
Low: $1.02
High: $1.30

2 Week Range

Now: $1.30
Low: $0.73
High: $2.29

Volume

309,231 shs

Average Volume

256,344 shs

Market Capitalization

$78.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.77